TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19006470

Group type: EXPERIMENTAL
Intervention: 4 g of omega-3-acid ethyl esters (P-OM3) with 80 mg atorvastatin daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: 80 mg atorvastatin daily
Number of subjects: 50
Study: 16049685

Group type: EXPERIMENTAL
Intervention: Adenoidectomy-tonsillectomy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Tonsillectomy alone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adenoidectomy alone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Routine histological examination
Number of subjects: 400
Study: 12548212

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (20 microg every 2 hours, increased to 40 microg depending on uterine contractions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal dinoprostone (2 mg twice, 6 hours apart)
Number of subjects: 200
Study: 10373048

Group type: EXPERIMENTAL
Intervention: Psychomotor test (10 min duration)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Psychomotor test
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (clinical examination)
Number of subjects: 80
Study: 8561069

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.5 g/d for 2 months)
Number of subjects: 12
Study: 1652597

Group type: EXPERIMENTAL
Intervention: Combined estrogen and progestin (conjugated equine estrogens, 2.5 mg/day and medroxyprogesterone acetate, 60 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Estrogen (conjugated equine estrogens, 2.5 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Progestin (medroxyprogesterone acetate, 60 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7039527

Group type: EXPERIMENTAL
Intervention: Penicillin prophylaxis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 29360046

Group type: EXPERIMENTAL
Intervention: Augmented prescriptive knowledge of performance feedback (PKP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Knowledge of results feedback only (Control)
Number of subjects: 31
Study: 28002472

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Educational Control (EC)
Number of subjects: 106
Study: 23556467

Group type: EXPERIMENTAL
Intervention: Bio-Oss(®) Collagen (graft material not included)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no grafting performed)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bio-Oss(®) Collagen (graft material included)
Number of subjects: 25
Study: 22922768

Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (7 mg daily for the first 10 days of each month for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid and/or immunosuppressive therapy (control group)
Number of subjects: 40
Study: 20519806

Group type: EXPERIMENTAL
Intervention: Miglitol (M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol and Sitagliptin (M+S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 18230824

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED, 800 kcal/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Weight loss (3 years)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Combined analysis of both groups
Number of subjects: 93

Group type: COMPARATOR
Intervention: Weight loss (short- and long-term)
Number of subjects: 93
Study: 16394405

Group type: EXPERIMENTAL
Intervention: Formulation C (mometasone furoate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation A (mometasone furoate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation D (mometasone furoate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 0
Study: 15590180

Group type: EXPERIMENTAL
Intervention: gemcitabine with doxifluridine
Number of subjects: 48

Group type: COMPARATOR
Intervention: paclitaxel with doxifluridine
Number of subjects: 48
Study: 10767241

Group type: EXPERIMENTAL
Intervention: Oral appliances with 2-mm mandibular advancement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral appliances with 4-mm mandibular advancement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral appliances with 6-mm mandibular advancement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral appliances (all advancements)
Number of subjects: 37
Study: 9130733

Group type: EXPERIMENTAL
Intervention: GnRH-a plus EE-CPA pill
Number of subjects: 24

Group type: COMPARATOR
Intervention: EE-CPA pill alone
Number of subjects: 24
Study: 8452318

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide as dry powder (400 micrograms daily, one inhalation/nostril/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide as aerosol (400 micrograms daily, two puffs/nostril/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not applicable, both groups received active treatment)
Number of subjects: 60
Study: 3021501

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg q.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29682715

Group type: EXPERIMENTAL
Intervention: Reinforcing sutures
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (no reinforcing sutures)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (high-risk group)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Reinforcing sutures (high-risk group)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Reinforcing sutures (low-risk group)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (low-risk group)
Number of subjects: 291
Study: 26795282

Group type: EXPERIMENTAL
Intervention: efavirenz, maraviroc or maraviroc+raltegravir with fixed-dose tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: maraviroc
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (HIV- controls)
Number of subjects: 32
Study: 24532547

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg once daily for 8 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (once daily for 8 days)
Number of subjects: 16
Study: 23520776

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (simple mandibular fractures)
Number of subjects: 20
Study: 20546629

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for ACR
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for INR
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for HbA1c
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for Lipids
Number of subjects: 4968

Group type: COMPARATOR
Intervention: Usual testing practice through a pathology laboratory
Number of subjects: 4968
Study: 18800217

Group type: EXPERIMENTAL
Intervention: Brief image-based multiple-behavior intervention (MBI)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 303
Study: 16158375

Group type: EXPERIMENTAL
Intervention: Walking at 2.7 km/h, 3.6 km/h, and 4.5 km/h (speed variation)
Number of subjects: 47
Study: 14521272

Group type: EXPERIMENTAL
Intervention: Learning impaired (LI) children
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-learning impaired (NLI) children
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Visual-motor correlation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Visual-motor correlations in NLI group
Number of subjects: 240
Study: 10463000

Group type: EXPERIMENTAL
Intervention: ThinPrep method
Number of subjects: 972

Group type: COMPARATOR
Intervention: Conventional Papanicolaou smears
Number of subjects: 972
Study: 8526786

Group type: EXPERIMENTAL
Intervention: Lactate hemofiltration (HF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bicarbonate hemofiltration (HF)
Number of subjects: 6
Study: 2371077

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (n = 10, mean age 21 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nebulized saline (n = 10, mean age 19 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (n = 7, mean age 22 weeks)
Number of subjects: 27
Study: 278459

Group type: EXPERIMENTAL
Intervention: Atropine 0.0075 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atropine 0.02 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg to 0.02 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atropine (various dosages)
Number of subjects: 100
Study: 29938420

Group type: EXPERIMENTAL
Intervention: Intramuscular 17‐alpha hydroxyprogesterone
Number of subjects: 132

Group type: COMPARATOR
Intervention: Intramuscular Neurobion
Number of subjects: 132
Study: 26795937

Group type: EXPERIMENTAL
Intervention: Internet-based training with CBT supervision via Skype (IBT-S)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Internet-based training with use of a consultation worksheet (IBT-CW)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Delayed-training controls (DTs)
Number of subjects: 61
Study: 24068472

Group type: EXPERIMENTAL
Intervention: FeNO group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 146
Study: 22717414

Group type: EXPERIMENTAL
Intervention: Ringer lactate solution at 240 mL per hour (group 4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intravenous hydration (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (any group)
Number of subjects: 120
Study: 20393152

Group type: EXPERIMENTAL
Intervention: Elevated fasting glucose levels in nondiabetic individuals
Number of subjects: 8447

Group type: EXPERIMENTAL
Intervention: Insulin resistance (homeostasis model assessment index)
Number of subjects: 8447

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 8447
Study: 18499399

Group type: EXPERIMENTAL
Intervention: ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron)
Number of subjects: 18
Study: 15925562

Group type: EXPERIMENTAL
Intervention: Celacade (immune modulation therapy)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 14728394

Group type: EXPERIMENTAL
Intervention: Diabetes management tool developed for a Personal Digital Assistant (PDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10515014

Group type: EXPERIMENTAL
Intervention: Milwaukee brace
Number of subjects: 102

Group type: COMPARATOR
Intervention: Boston brace
Number of subjects: 102

Group type: COMPARATOR
Intervention: TLSO
Number of subjects: 102

Group type: COMPARATOR
Intervention: Charleston bending orthosis
Number of subjects: 102
Study: 7733032

Group type: EXPERIMENTAL
Intervention: High dose of vitamin A
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 2178916

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study: 7433340

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 17
Study: 6441523

Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 30393950

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo (discontinuing sitagliptin)
Number of subjects: 743
Study: 30297834

Group type: EXPERIMENTAL
Intervention: Sodium‐Butyrate (SB) added to milk replacer
Number of subjects: 16
Study: 25604346

Group type: EXPERIMENTAL
Intervention: Bromelain (1000 mg·day(‐1))
Number of subjects: 15
Study: 24571917

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active recovery (AR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Passive rest (PR)
Number of subjects: 9
Study: 22744992

Group type: EXPERIMENTAL
Intervention: Wii-fit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seated exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 20089725

Group type: EXPERIMENTAL
Intervention: Dietary intake of total protein
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of lactose
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of calcium
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of sodium
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of total fat
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of dietary fiber
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Dietary intake of vegetable protein
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Body mass index-for-age percentile
Number of subjects: 159
Study: 17352404

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP), 4 capsules of 28 mg (total 112 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tobramycin solution for inhalation (TSI), 300 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 90
Study: 16286669

Group type: EXPERIMENTAL
Intervention: EVA (560 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 46
Study: 11856066

Group type: EXPERIMENTAL
Intervention: Infants with VLBW and high gestational age
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Infants with VLBW and low gestational age
Number of subjects: 44

Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 44
Study: 10325894

Group type: EXPERIMENTAL
Intervention: Supervised aerobic training (group 1, n = 26)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untrained group (group 2, n = 16)
Number of subjects: 42
Study: 7622632

Group type: EXPERIMENTAL
Intervention: Oral hygiene and scaling
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Full initial therapy including root planning
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 2645848

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (0.5 mg/kg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (0.6 mg/kg/d increased to 2.0 mg/kg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate and Fenfluramine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 20
Study: 353461

Group type: EXPERIMENTAL
Intervention: Stenoptin (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Number of subjects: 20
Study: 31361631

Group type: EXPERIMENTAL
Intervention: Supraclavicular block (SCB)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 103
Study: 28155333

Group type: EXPERIMENTAL
Intervention: Zofenopril 30-60 mg daily
Number of subjects: 3542

Group type: EXPERIMENTAL
Intervention: Lisinopril 5-10 mg daily
Number of subjects: 3542

Group type: COMPARATOR
Intervention: Ramipril 10 mg daily
Number of subjects: 3542

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 3542
Study: 26168925

Group type: EXPERIMENTAL
Intervention: Training group (5 attempts)
Number of subjects: 52
Study: 23684280

Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 22

Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 22
Study: 21793387

Group type: EXPERIMENTAL
Intervention: Jin's 'Sanzhen' therapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Combination of Jin's 'Sanzhen' therapy and rehabilitation training
Number of subjects: 254
Study: 19141327

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 744

Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 744
Study: 17162058

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15162076

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 10795118

Group type: EXPERIMENTAL
Intervention: epirubicin 90 mg/m2-paclitaxel 175 mg/m2; 4 cycles bi-weekly, supported by G-CSF 5 micrograms/kg day 5-13 and 3 sequential cycles of CMF 600/40/600 mg/m2 at 2-weeks interval
Number of subjects: 127

Group type: COMPARATOR
Intervention: epirubicin 90 mg/m2-cyclophosphamide 600 mg/m2; 4 cycles tri-weekly, and 3 sequential cycles of CMF 600/40/600 mg/m2 at 3-weeks interval
Number of subjects: 127
Study: 9398893

Group type: EXPERIMENTAL
Intervention: Clarithromycin and omeprazole
Number of subjects: 208

Group type: COMPARATOR
Intervention: Omeprazole and placebo
Number of subjects: 208
Study: 1549937

Group type: EXPERIMENTAL
Intervention: oral clonidine 300 micrograms 120 min before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: oral diazepam 0.15 mg/kg 120 min before surgery
Number of subjects: 100
Study: 3994920

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29232560

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in women
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (saline) in women
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in men
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (saline) in men
Number of subjects: 96
Study: 28233454

Group type: EXPERIMENTAL
Intervention: High MUFA (HMUFA) diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 PUFA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet (placebo)
Number of subjects: 75

Group type: COMPARATOR
Intervention: High SFA (HSFA) diet
Number of subjects: 75
Study: 26123177

Group type: EXPERIMENTAL
Intervention: Efron's biased coin design with varying bias p (0.5 to 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efron's biased coin design
Number of subjects: 0
Study: 24293753

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 14
Study: 21196081

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment initiation and engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment engagement
Number of subjects: 0
Study: 18958548

Group type: EXPERIMENTAL
Intervention: Group H (prednisolone > or =10,000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group L (prednisolone <10,000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls (healthy subjects)
Number of subjects: 30
Study: 17000365

Group type: EXPERIMENTAL
Intervention: Tissue synchronization imaging (TSI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prolonged QRS duration (> 120 ms)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Narrow QRS duration (< 120 ms)
Number of subjects: 100

Group type: COMPARATOR
Intervention: QRS criteria alone
Number of subjects: 100
Study: 12947997

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injection immunotherapy
Number of subjects: 0
Study: 11028131

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNβ‐1b)
Number of subjects: 2000
Study: 8826307

Group type: EXPERIMENTAL
Intervention: Partners in Care Practice Model (PIPC)
Number of subjects: 0
Study: 1576099

Group type: EXPERIMENTAL
Intervention: nifedipine-SR (10 mg b.i.d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nifedipine-SR
Number of subjects: 10
Study: 2867037

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 683

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 683
Study: 31097338

Group type: EXPERIMENTAL
Intervention: 20% albumin fluid bolus therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid fluid bolus therapy
Number of subjects: 100
Study: 30315670

Group type: EXPERIMENTAL
Intervention: 100 mg/day of DHEA for 28 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DHEA administration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DHEA and T concentrations
Number of subjects: 11
Study: 27010682

Group type: EXPERIMENTAL
Intervention: Ozone gas bath combined with EVLT
Number of subjects: 92

Group type: COMPARATOR
Intervention: EVLT alone
Number of subjects: 92
Study: 24981311

Group type: EXPERIMENTAL
Intervention: Cisplatin/leucovorin/5-FU (FLP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fluorouracil/leucovorin/oxaliplatin (FLO)
Number of subjects: 72
Study: 22177821

Group type: COMPARATOR
Intervention: Propofol-saline solution admixture (Group A - Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10:1 propofol-ketamine ratio (Group B)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 5:1 propofol-ketamine ratio (Group C)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3:1 propofol-ketamine ratio (Group D)
Number of subjects: 64
Study: 20451469

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Needling at specific points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in neurotransmitters and biological response modifiers
Number of subjects: 0